Longboard Pharmaceuticals Inc (LBPH) Stock News

USA - NASDAQ:LBPH - US54300N1037 - Common Stock

59.98 USD

+0.02 (+0.03%)

Last: 11/29/2024, 7:46:54 PM

60.01 USD

+0.03 (+0.05%)

After Hours: 11/29/2024, 7:46:54 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LBPH Latest News, Press Relases and Analysis

All

Press Releases

9 months ago - By: Benzinga - Mentions: FYBR BLCO APO NVAX ...

Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt

10 months ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

10 months ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

a year ago - By: Rowley Law PLLC

News Image

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Longboard Pharmaceuticals, Inc.

11 months ago - By: Kahn Swick & Foti, LLC

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

a year ago - By: Benzinga - Mentions: APO USAP AMPS BHC ...

Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags

a year ago - By: Halper Sadeh LLC - Mentions: ARC

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LBPH and ARC on Behalf of Shareholders

a year ago - By: Kahn Swick & Foti, LLC

LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPH

a year ago - By: Investor's Business Daily

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record

a year ago - By: Ademi LLP

Shareholder Alert: Ademi LLP Investigates Whether Longboard Pharmaceuticals, Inc. Is Obtaining a Fair Price for Its Public Shareholders

a year ago - By: Halper Sadeh LLC

LBPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Longboard Pharmaceuticals, Inc. Is Fair to Shareholders

a year ago - By: Bloomberg

Lundbeck to Buy Longboard Pharmaceuticals in $2.6 Billion Deal

a year ago - By: Longboard Pharmaceuticals, Inc.

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

a year ago - By: Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1